Examining the future of the global pharma industry as two of the world’s biggest superpowers come to blows.
Key Points:
According to a new Pew Research Center survey in Q12021, 9 of 10 US adults (89%) considered China a competitor or enemy rather than a partner during the pandemic.
Still, in 2020, Chinese FDI in the US stood at the third position in pharma med-devices at $625 million despite the scrutiny tied to FIRRMA (Foreign Investment Risk Review Modernization Act).
This perception-based negativity will not impact the market. “Go China and No China” will soon be replaced by “No clarity over China.”
Immunotherapy has emerged as a promising treatment for cancer, with immune checkpoint inhibitors (ICIs) dominating the market. The market is projected to...
The introduction of vaccines for key diseases, such as meningococcal meningitis A, hepatitis E, and malaria, in recent years has helped to reduce mortality...
